Use of salts of n-(3-(4-(3-(diisobutylamino) propyl) piperazin-1-yl) propyl)-1h-benzo [d] imidazole-2-amine and solvates thereof for treatment of sensory neuronal diseases
By using N-(3-(4-(3-(4-(3-(diisobutylamino)propyl)piperazine-1-yl)propyl)-1H-benzo[d]imidazole-2-amine salt and its solvents Chemicals solve the shortcomings in the treatment and prevention of sensory neuron diseases, significantly improve neuronal survival and neurite network integrity, and provide effective treatment and prevention for specific diseases.
Patent Information
- Application Number
- CN202380029647.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-25
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-12
AI Technical Summary
Existing methods for treating and preventing sensory neuronal diseases are limited, especially for Sjogren's syndrome, celiac disease, and chemotherapy-induced peripheral neuropathy.
The salt of N-(3-(4-(3-(4-(3-(diisobutylamino)propyl)piperazine-1-yl)propyl)-1H-benzo[d]imidazole-2-amine and its pharmacy Acceptable solvates are used to treat and prevent sensory neuron diseases by promoting the survival of sensory neurons and Schwann cells.
It significantly improves the survival rate of sensory neurons and the integrity of neurite networks, and provides effective treatment and prevention means for diseases such as Sjogren's syndrome, celiac disease, and chemotherapy-induced peripheral neuropathy.
Smart Images

Figure BDA0005055261180000091 
Figure BDA0005055261180000101 
Figure BDA0005055261180000171
Abstract
Description
[0001] The present invention relates to a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and a pharmaceutically acceptable solvate thereof, and a novel use thereof in treating and / or preventing sensory neuron diseases. Background Art
[0002] Sensory neurons (SN) are neuronal cells present in the peripheral nervous system (PNS) with different functions. The sensory components of the PNS include the visceral sensory system and several other organs, which innervate the tympanic membrane, lungs, digestive tract and urinary tract; and the somatosensory system, which transmits the sensation of touch pain and other stimuli (such as temperature and air movement). Different types of sensations are driven by neuronal subtypes, which differ in the innervation of end organs, axon terminal morphology, cell-to-cell interactions within the dorsal root ganglion (DRG), and the innervation pattern of the dorsal horn of the spinal cord and the brainstem. SN contains many axons of neighboring Schwann cells, which can be myelin cells or non-myelin cells. Myelin is a lipid-rich insulating layer surrounding the axons, which increases the conduction velocity and reduces the energy requirements of membrane repolarization. Myelinating Schwann cells wrap the axons of sensory neurons to form a protective myelin sheath. Schwann cells also play an important role as a cell matrix and play a role in nerve conduction, neural development and regeneration.
[0003] Sensory neuron disease (SND) is a peripheral nervous system disease that causes sensory neuron dysfunction, degeneration and final apoptosis. As a result, the sensation of temperature, pain or vibration can be changed. SND includes peripheral sensory neuron lesions or ganglioneurosis, which is characterized by primary and selective degeneration of DRG T-shaped neurons and their projections, usually resulting in multifocal sensory disturbances in the limbs. Some SND mainly targets the axonal region and is therefore referred to as peripheral axonopathy, which causes axonal degeneration according to the Wallerian process or its equivalent process. In addition, if the axon is damaged or destroyed, Schwann cells will no longer support myelin. Wallerian degeneration, etc. further triggers Schwann cells to be reprogrammed into a demyelinating phenotype, thereby causing myelin loss. Some SNDs relate to demyelinating processes and are referred to as peripheral myelin diseases.
[0004] Causes of SND include genetic predisposition, autoimmune diseases such as Sjögren's syndrome and celiac disease, and xenobiotic-related toxicity. Exposure to various neurotoxic agents leads to the onset of toxic peripheral neuropathy, altering neurons, axons, Schwann cells, and / or myelin. Indeed, chemicals (compounds such as arsenic, mercury, or tin derivatives) remain a problem of mishandling due to their neurotoxic properties, especially in some developing countries.
[0005] Another form of toxic peripheral neuropathy is chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a common side effect of many chemotherapy regimens. In fact, cancer patients treated with platinum-based antineoplastic agents, vinca alkaloids, epothilones, or taxanes often suffer from neuropathy caused by these molecules. In addition, cancer survivors may require lifelong medical monitoring, especially with platinum-based anticancer agents and taxanes, because CIPN may persist for years after chemotherapy.
[0006] There is no specific treatment available for sensory neuron disease, other than symptomatic medications to reduce pain and inflammation.
[0007] N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sulfate and solvates thereof previously disclosed in WO 2014 / 102339 are useful for the treatment and / or prevention of neurodegenerative diseases, amyloid diseases, tauopathies and developmental diseases. These compounds are particularly beneficial for Alzheimer's disease, Parkinson's disease and tauopathies: a Phase 2A clinical trial of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulfate in patients with progressive supranuclear palsy (PSP) is ongoing.
[0008] These salts are able to modulate Tau phosphorylation and increase progranulin (PGRN) neurotrophic factor levels, a deficiency of which is known to accelerate Tau deposition and phosphorylation, as demonstrated in mice expressing human tau (J. Neuropathol. Exp. Neurol. 74, 158–165 (2015). Therefore, these compounds are particularly useful for treating tauopathies.
[0009] Since there is still a need in the art for chemical entities that can be used to treat or prevent sensory neuron diseases, the applicants have investigated the possibility of using salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and their solvates for this purpose. Summary of the invention
[0010] The present invention is based on the unexpected discovery that salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine have a neuroprotective effect on sensory neurons.
[0011] Therefore, the present invention relates to salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and solvates thereof for use in the treatment and / or prevention of sensory neuron diseases. DETAILED DESCRIPTION
[0012] Applicants have demonstrated that salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof exert beneficial effects on primary cultures of sensory neurons and Schwann cells by promoting their survival and the integrity of their neurite networks after injury induced by chemotherapeutic agents.
[0013] All these findings support that salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof may be effective therapies for improving sensory neuron diseases and therefore may be useful as drugs, particularly for the treatment or prevention of sensory neuron diseases.
[0014] Sensory neuron diseases include, but are not limited to, neuropathy caused by Sjögren's syndrome, celiac disease neuropathy, toxic peripheral neuropathy, and chemotherapy-induced peripheral neuropathy (CIPN).
[0015] Sjögren's syndrome Sjögren's syndrome is a heterogeneous autoimmune inflammatory disease that often affects peripheral nerves with a wide range of sensory morphologies and distribution patterns. Neuropathy caused by Sjögren's syndrome can be neuronopathy, axonopathy, and / or myelinopathy (Seeliger et al. Frontiers in Immunology 2019, Vol. 10, Article 1600).
[0016] Celiac neuropathy refers to neuronopathy, chronic inflammatory demyelinating neuropathy, autonomic neuropathy, and mononeuritis multiplex, all caused by celiac disease. Celiac disease is an autoimmune gastrointestinal disorder in which damage to the lining of the small intestine results in inadequate absorption of essential proteins, fats, carbohydrates, vitamins, and minerals from food.
[0017] Toxic peripheral neuropathy refers to neuropathy caused by exposure to chemical nerve agents. Toxic peripheral neuropathies include toxic peripheral axonopathy, especially caused by hexane, 2-hexanone, carbon disulfide, and 1-bromopropane; toxic peripheral myelinopathy, especially caused by hexachlorophene, triethyltin, tellurium, diphtheria toxin, disulfiram, N,N-diethyldithiocarbamate, lysolecithin, ethidium bromide; toxic peripheral neuronopathy, especially caused by methylmercury and catecholamines.
[0018] Chemotherapy-induced peripheral neuropathy (CIPN) refers to peripheral neuropathy caused by common chemotherapeutic agents, including platinum-based antineoplastic agents, vinca alkaloids, epothilones (such as ixabepilone), taxanes, proteasome inhibitors (such as bortezomib and carfilzomib) and immunomodulatory drug thalidomide. CIPN is the main reason for stopping antineoplastic therapy or changing dosage regimens. CIPN is partially reversible, but damage may be irreversible in the worst case. More than half of the patients treated with antimitotic drugs describe paresthesia and dysesthesia, which occur 24-72 hours after administration. There is no therapy to prevent CIPN on the market. CIPN preferentially occurs in dorsal root ganglia (DRG), sensory neurons, satellite cells and Schwann cells (SC). CIPN includes chemotherapy-induced axonopathy caused by taxanes (such as paclitaxel and docetaxel), vinca alkaloids (such as vinblastine, vinflunine and vinorelbine), and chemotherapy-induced neuronopathy caused by platinum-based antineoplastic agents (such as cisplatin, oxaliplatin and carboplatin).
[0019] In one embodiment, the present invention relates to a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine as defined herein, or a pharmaceutically acceptable solvate thereof, for use in the treatment and / or prevention of a sensory neuron disease, in particular selected from the group consisting of: neuropathy caused by Sjögren's syndrome, celiac neuropathy, toxic peripheral neuropathy and chemotherapy-induced peripheral neuropathy (CIPN). Preferably, the disease is selected from the group consisting of: neuropathies caused by Sjögren's syndrome, neuropathies caused by celiac disease, toxic peripheral neuropathies, chemotherapy-induced peripheral neuropathy (CIPN). More preferably, the disease is selected from the group consisting of: neuropathies caused by Sjögren's syndrome, neuropathies caused by celiac disease, toxic peripheral neuropathies, chemotherapy-induced peripheral neuropathy (CIPN). More preferably, the disease is selected from the group consisting of: neuropathies caused by Sjögren's syndrome, neuropathies caused by celiac disease, toxic peripheral neuropathies, axonopathy induced by chemotherapy caused by taxanes and vinca alkaloids, and chemotherapy-induced neuropathies caused by platinum-based antineoplastic agents. More preferably, the disease is selected from the group consisting of: neuropathies caused by Sjögren's syndrome, neuropathies caused by celiac disease, toxic peripheral neuropathies, and chemotherapy-induced neuropathies caused by platinum-based antineoplastic agents. More preferably, the disease is selected from: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, and chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents. Even more preferably, the disease is selected from chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents.
[0020] In other aspects, the present invention also provides a method for treating and / or preventing sensory neuron diseases, in particular the above-cited and embodiments thereof, comprising administering to a patient in need thereof a pharmaceutically effective amount of a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine as described herein or a pharmaceutically acceptable solvate thereof. In a specific embodiment, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents.
[0021] In other aspects, the present invention also provides the use of a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine as described herein or a pharmaceutically acceptable solvate thereof in the preparation of a drug for treating and / or preventing sensory neuron diseases, in particular the above-cited and embodiments thereof. In a specific embodiment, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, and chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents.
[0022] In a specific embodiment, the present invention also relates to a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine as defined herein, or a pharmaceutically acceptable solvate thereof, for use in delaying the onset of a sensory neuron disease in a patient, in particular selected from the following: neuropathy caused by Sjögren's syndrome, celiac neuropathy, toxic peripheral neuropathy and chemotherapy-induced peripheral neuropathy (CIPN). Preferably, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, chemotherapy-induced peripheral neuropathy (CIPN). More preferably, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, chemotherapy-induced axonopathy caused by taxanes and vinca alkaloids, chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents. More preferably, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents. More preferably, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents. Even more preferably, the disease is selected from chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents.
[0023] In other aspects, the present invention provides a method for delaying the onset of a sensory neuron disease in a patient, particularly the above-cited and embodiments thereof, comprising administering to a patient in need thereof a pharmaceutically effective amount of a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine salt or a pharmaceutically acceptable solvate thereof. In a specific embodiment, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents.
[0024] In other aspects, the present invention also provides the use of a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine as described herein or a pharmaceutically acceptable solvate thereof in the preparation of a medicament for delaying the onset of a sensory neuron disease in a patient, in particular the above-cited embodiments thereof. In a specific embodiment, the disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, chemotherapy-induced neuronopathy caused by platinum-based anti-tumor agents.
[0025] According to one embodiment, a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and a pharmaceutically acceptable solvate thereof may be administered as part of a combination therapy. Thus, embodiments comprising co-administration of a composition and a medicament are included within the scope of the invention, wherein the composition and medicament contain, in addition to a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof as an active ingredient, other therapeutic agents and / or active ingredients. Such multi-drug regimens, often referred to as "combination therapy," may be used to treat and / or prevent any sensory neuron disease. The use of such a combination of therapeutic agents is particularly useful for treating the above-mentioned sensory neuron diseases in patients in need of treatment or at risk of becoming such patients.
[0026] In addition to the need for therapeutic efficacy, which may require the use of an active agent other than a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof, there may be other reasons that necessitate or strongly suggest the use of a drug combination involving active ingredients as an adjunctive therapy, i.e., one that supplements and augments the action performed by a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof. Suitable adjunctive therapeutic agents for adjunctive therapeutic purposes include drugs that treat, instead of directly treating and / or preventing a disease or condition mediated by or associated with sensory neuron degeneration, a disease or condition that is directly caused by or indirectly accompanies such degeneration.
[0027] According to another feature of the present invention, the salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and its pharmaceutically acceptable solvate can be used in combination therapy with other drugs. More particularly, the compound of Formula I or Formula II and its pharmaceutically acceptable solvate can be used as an adjuvant therapy in combination with a chemotherapeutic agent, the chemotherapeutic agent including platinum-based anti-tumor agents such as cisplatin, oxaliplatin and carboplatin, vinca alkaloids such as vinblastine, vinflunine and vinorelbine, epothilones such as ixabepilone, taxanes such as paclitaxel and docetaxel, proteasome inhibitors such as bortezomib and carfilzomib; and immunomodulatory drug thalidomide.
[0028] Thus, the methods of treatment and pharmaceutical compositions of the present invention can use a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof in a monotherapy for sensory neuron disease. However, the methods and compositions can also be used in multiple therapies, wherein one or more salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof is co-administered in combination with one or more other therapeutic agents.
[0029] In the above embodiment, the combination of a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazine-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof and other therapeutically active agents can be administered in separate or combined dosage forms and in a sequential or simultaneous manner with respect to their administration time. Thus, the administration of one component agent can be before, at the same time, or after the administration of the other component agents.
[0030] Typically, for pharmaceutical use, a salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof can be formulated as a pharmaceutical composition comprising at least one salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and / or adjuvant, and optionally one or more other therapeutic agents and / or active ingredients.
[0031] By way of non-limiting example, the pharmaceutical composition may be in a dosage form suitable for oral administration, parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), topical administration, administration by inhalation, skin patch, implant, suppository, etc. Such suitable administration forms (which may be solid, semi-solid or liquid, depending on the mode of administration) as well as methods and carriers, diluents and excipients for their preparation are clear to those skilled in the art; reference is made to the latest edition of Remington's Pharmaceutical Sciences. The pharmaceutical composition may be formulated in solid form and re-dissolved or suspended before use. Preferred pharmaceutical compositions of the succinate salt or its solvate of the present invention are solid dosage forms suitable for oral administration.
[0032] Some preferred but non-limiting examples of dosage forms include tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, creams, lotions, soft and hard gelatin capsules, suppositories, drops, sterile injectable solutions and sterile packaged powders (which are usually reconstituted before use) for administration as a bolus and / or for continuous administration, which can be formulated with carriers, excipients and diluents which are themselves suitable for such formulations, such as lactose, glucose, sucrose, sorbitol, mannitol, starch, agar, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, polyethylene glycol, cellulose, (sterile) water, methylcellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate, edible oils, vegetable oils and mineral oils, or suitable mixtures thereof. Particularly preferred dosage forms of the succinate salt and its solvate of the present invention are soft capsules and hard capsules, in particular soft gelatin capsules and hard gelatin capsules, preferably hard gelatin capsules, which are filled with at least one microcrystalline cellulose excipient, in particular PH101 preparation. The pharmaceutical composition may optionally contain other substances commonly used in pharmaceutical preparations, such as lubricants, wetting agents, emulsifiers and suspending agents, dispersants, disintegrants, stabilizers, isotonic agents, expanders, fillers, preservatives, sweeteners, flavoring agents, fragrances, colorants, antibacterial and / or antifungal agents (such as parabens, chlorobutanol, phenol, sorbic acid), dispensing agents, flow regulators, release agents, etc. The composition can also be formulated to provide rapid, sustained or delayed release of the active compound contained therein.
[0033] The pharmaceutical composition of the present invention is preferably in unit dosage form and can be appropriately packaged, for example, in a box, blister, vial, bottle, sachet, ampoule or any other suitable single-dose or multi-dose holder or container (which can be appropriately labeled); optionally, one or more instructions containing product information and / or instructions for use. Typically, such a unit dose will contain 0.05-1000 mg, typically 1-500 mg of at least one compound of the present invention, for example about 10, 25, 50, 100, 200, 300 or 400 mg per unit dose.
[0034] In general, depending on the condition to be prevented or treated and the route of administration, the active compound of the invention will generally be administered at 0.01-100 mg / kg, more usually 0.1-50 mg, such as 1-25 mg, for example about 0.5, 1, 2, 5, 10, 15, 20 or 25 mg / kg patient body weight / day, which can be administered as a single daily dose, divided into one or more daily doses, or administered essentially continuously, for example using instillation.
[0035] In one embodiment, the salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine is N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sulfate and pharmaceutically acceptable solvates thereof.
[0036] In a preferred embodiment, the sulfate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine is of Formula I.
[0037]
[0038] wherein x is 0.5-4, preferably x is 0.5-3.5, and more preferably x is 0.9-3.
[0039] In other aspects, for one molecule of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, the sulfate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine contains 0.5-4 equivalents, preferably 0.5-3.5 equivalents, and more preferably 0.9-3 equivalents of sulfate.
[0040] In a preferred embodiment, x is 1.7-2.3, preferably x is 1.9-2.1, more preferably x is about 2 or x is 2,
[0041] In a particularly preferred embodiment, the sulfate is N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulfate.
[0042] In one embodiment, the sulfate of formula I is in the form of a pharmaceutically acceptable solvate, preferably a hydrate. For 1 molecule of sulfate of formula I, the solvate stoichiometry is 0.5-5, preferably 1-4, more preferably 1.5-2.5, still more preferably 1.8-2.2, even more preferably 2 or about 2 molecules of solvate.
[0043] In another embodiment, the salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine is N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine succinate and pharmaceutically acceptable solvates thereof.
[0044] In a preferred embodiment, the succinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine is of Formula II:
[0045]
[0046] wherein y is 1-4, preferably y is 1.4-3.1, more preferably y is 1.4-1.6, still more preferably y is about 1.5, even more preferably y is 1.5.
[0047] In other words, for one molecule of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, the succinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine contains 1-4 equivalents, preferably 1.4-3.1 equivalents, more preferably 1.4-1.6 equivalents, still more preferably about 1.5 equivalents, and even more preferably 1.5 equivalents of succinate.
[0048] In a preferred embodiment, the succinate salt of formula II is the sesquisuccinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine.
[0049] In one embodiment, the preferred succinate salt is a compound of formula II wherein x is 2.9-3.1, preferably wherein x is about 3, more preferably x is 3.
[0050] In another preferred embodiment, the succinate salt is the trisuccinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine.
[0051] In a specific embodiment, the succinate of formula II is in the form of a pharmaceutically acceptable solvate, preferably a hydrate. For 1 molecule of the succinate of formula II, the solvate stoichiometry is 0.4-2, preferably 0.4-1.2, more preferably 0.5-1.1, still more preferably about 0.5 or about 1.1, even more preferably 0.5 or 1.1 molecules of solvate.
[0052] In one embodiment, the succinate salt of Formula II is N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sesquisuccinate hemihydrate.
[0053] In another embodiment, the succinate salt of Formula II is N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sesquisuccinate monohydrate.
[0054] In one embodiment, a particularly preferred succinate salt is a compound of formula II, wherein y is 1.5, and when irradiated with a CuKα light source, its crystalline form has an X-ray powder diffraction (XRPD) pattern comprising diffraction angles at 2θ=3.8°±0.2°, 10.3°±0.2°, 12.4°±0.2°, 16.2°±0.2°, 17.9°±0.2°, 19.8°±0.2°, 20.4°±0.2°, 23.8°±0.2° and 26.7°±0.2°. This particular crystalline form is referred to throughout this application as "Form 1", and its XRPD diffraction pattern recorded on a PANalytical X'pert pro with a PIXcel detector (128 channels) is as follows Figure 1 as shown in .
[0055] Another preferred succinate salt is a compound of formula II, wherein y is 3, and when irradiated with a CuKα light source, its crystalline form has an X-ray powder diffraction (XRPD) pattern comprising diffraction angles at 2θ=5.3°±0.2°, 15.0°±0.2°, 15.3°±0.2°, 16.8°±0.2°, 17.9°±0.2°, 20.5°±0.2°, 21.2°±0.2°, 23.9°±0.2°, 24.3°±0.2° and 26.6°±0.2°. This particular crystalline form is referred to throughout this application as "Form 2", and the XRPD diffraction pattern recorded on a PANalytical X'pert pro with a PIXcel detector (128 channels) is as follows Figure 2 as shown in .
[0056] Another preferred succinate salt is a hemihydrate of the compound of formula II, wherein y is 1.5, and when irradiated with a CuKα light source, its crystalline form has an X-ray powder diffraction (XRPD) pattern comprising diffraction angles at 2θ=3.8°±0.2°, 4.4°±0.2°, 9.2°±0.2°, 10.6°±0.2°, 13.8°±0.2°, 17.7°±0.2°, 19.9°±0.2°, 21.6°±0.2° and 23.6°±0.2°. Its XRPD diffraction pattern recorded on a PANalytical X'pert pro with a PIXcel detector (128 channels) is as follows Figure 3 as shown in .
[0057] Another preferred succinate salt is a monohydrate compound of formula I, wherein y is 1.5, and when irradiated with a CuKα light source, its crystalline form has an X-ray powder diffraction (XRPD) pattern comprising diffraction angles at 2θ=4.2±0.2°, 4.4°±0.2°, 9.6°±0.2°, 10.6°±0.2°, 15.0°±0.2°, 16.3°±0.2°, 17.4°±0.2°, 19.7°±0.2°, 22.8°±0.2°, 29.1 and 29.7°±0.2° peaks. Its XRPD diffraction pattern recorded on a PANalytical X'pert pro with a PIXcel detector (128 channels) is as follows Figure 4 as shown in .
[0058] All references to compounds of the formula I and formula II include their solvates, in particular hydrates, multicomponent complexes and liquid crystalline forms thereof.
[0059] The compounds disclosed throughout this application are used Ultra version 11.0 (CambridgeSoft, Cambridge, MA, USA) named.
[0060] N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine free base can be obtained as disclosed in WO 2006 / 051489. Sulfate salt can be obtained as disclosed in WO 2014 / 102339. Succinate salt and solvates thereof can be prepared according to techniques known in the art, such as those involving precipitation, crystallization, recrystallization, freeze drying, phase transfer or ion exchange resins.
[0061] definition
[0062] The following definitions and explanations are for terms used throughout this application, including the specification, drawings, and claims.
[0063] Unless otherwise stated, any reference to a compound of the invention herein is intended to refer to a compound of formula I or II and a pharmaceutically acceptable solvate thereof. All references to a compound of formula I or II include references to pharmaceutically acceptable solvates thereof and all crystalline forms thereof.
[0064] The term "administration" or variations thereof (e.g., "administering") refers to providing an active agent or ingredient (e.g., N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine), alone or as part of a pharmaceutically acceptable composition, to a patient whose condition, symptom, or disease is to be treated or prevented.
[0065] The term "human" refers to subjects of both sexes and at any stage of development (ie, neonate, infant, juvenile, adolescent, adult).
[0066] The term "patient" refers to a warm-blooded animal, more preferably a human, who is awaiting or receiving medical care, or is / will be the subject of a medical procedure.
[0067] "Pharmaceutically acceptable" means that the ingredients of the pharmaceutical composition are compatible with each other and not deleterious to the patient thereof.
[0068] As used herein, the terms "prevent", "preventing" and "prevention" refer to a method of delaying or eliminating the onset of a condition or disease and / or its attendant symptoms, preventing a patient from acquiring a condition or disease, or reducing a patient's risk of acquiring a condition or disease.
[0069] As used herein, the expression "reduced" means partially reduced or completely reduced.
[0070] As used herein, the term "sesqui" refers to 1.5 times equivalents, and a sesquisuccinate salt of a compound refers to a succinic acid addition salt thereof, wherein succinic acid is present in a 3:2 ratio compared to the compound in its free base form.
[0071] The term "solvate" is used herein to describe a compound of the invention that contains a stoichiometric or substoichiometric amount of one or more pharmaceutically acceptable solvent molecules, such as ethanol. When the solvent is water, the term "hydrate" is used. Pharmaceutically acceptable solvent molecules can co-crystallize with the compound of the invention, and / or exist in its solid crystalline and / or amorphous phase, and / or be adsorbed thereon.
[0072] As used herein, the term "therapeutically effective amount" (or more simply "effective amount") means the amount of an active agent or ingredient (e.g., N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) that is sufficient to achieve the desired therapeutic or prophylactic effect in the patient to which it is administered.
[0073] As used herein, the terms "treat", "treating" or "treatment" are intended to include alleviating, reducing or eliminating a condition or disease and / or its attendant symptoms.
[0074] The present invention will be better understood with reference to the following examples. These examples are intended to represent specific embodiments of the present invention and are not intended to limit the scope of the invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1Shown is an XRPD 2θ diffraction pattern of Form 1 of the sesquisuccinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine.
[0076] Figure 2 Shown is an XRPD 2θ diffraction pattern of Form 2 of the trisuccinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine.
[0077] Figure 3 N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sesquisuccinate hemihydrate (0.5 equivalents of water) is shown.
[0078] Figure 4 N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sesquisuccinate monohydrate (1.1 equivalents of water) is shown.
[0079] Figure 5 The crystalline form 1 of the sesquisuccinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine is shown. 1 H-NMR spectrum (DMSO-d6, 500.12 MHz).
[0080] Figure 6 The crystalline form 1 of the sesquisuccinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine is shown. 13 C quantitative-NMR spectroscopy (DMSO-d6, 500.12 MHz).
[0081] Figure 7 The effects of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) disulfate incubated with cisplatin injury for 24 hours on the survival rate (A) and neurite network (B) of MAP-2 positive SN in primary cultures of rat sensory neurons and Schwann cells are shown. Results are expressed as a percentage of control and are mean ± SEM (n = 4-6 / group). One-way ANOVA followed by PLSD Fisher test.
[0082] Figure 8The effects of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) sesquisuccinate form 1 on the survival rate (A) and neurite network (B) of MAP-2 positive SN in primary cultures of rat sensory neurons and Schwann cells after 24 hours of incubation with cisplatin injury are shown. The results are expressed as a percentage of the control and are mean ± SEM (n = 5-6 / group). One-way ANOVA followed by PLSD Fisher test.
[0083] Chemical Examples
[0084] The following abbreviations are used throughout this application: °C: degrees Celsius, DMSO: dimethyl sulfoxide, δ: NMR chemical shift, expressed in ppm, eq: equivalent, EDTA: ethylenediaminetetraacetic acid, eq.: equivalent, g: gram, h: hour, HPLC: high performance liquid chromatography, Hz: hertz, L: liter, M: mol / L, mM: mmol / L, μM: μmol / L, Me: methyl, MEK: methyl ethyl ketone, mg: milligram, MHz: megahertz, min: minute, mL: milliliter, mm: millimeter, mol: mole, mmol: millimole, μg: microgram, μmol: micromole, nm: nanometer, NMR: nuclear magnetic resonance, PBS: phosphate buffered saline, PGRN: progranulin, ppm: parts per million, RH: relative humidity, RPM: revolutions per minute, rt: retention time, RT: room temperature (about 15-25 °C), s: second, TFA: trifluoroacetic acid, UV: ultraviolet, v: volume, XRPD: X-ray powder diffraction.
[0085] All reported temperatures are in degrees Celsius (°C); unless otherwise stated, all reactions were performed at room temperature (RT).
[0086] The experimental setup or purification procedures used in the present invention, when not described in specific details, are assumed to be known to the person skilled in the art and are described in such standard reference manuals as: i) Gordon, AJ; Ford, RA "The Chemist's Companion - A Handbook of Practical Data, Techniques, and References", Wiley: New York, 1972; ii) Vogel's Textbook of Practical Organic Chemistry, Pearson Prentice Hall: London, 1989; iii) P. Heinrich Stahl and Camille G. Wernuth 'Handbook of Pharmaceutical Salts', Wiley VCH.
[0087] HPLC analysis
[0088] Instrument: Dionex Ultimate 3000
[0089] Column: Supelco Ascentis Express C18 15x 4.6mm 2.7μm
[0090] Column temperature: 50°C
[0091] Autosampler temperature: ambient temperature
[0092] UV wavelength: 275nm
[0093] Injection volume: 20 μL
[0094] Flow rate: 1mL / min
[0095] Mobile phase A: 0.1% TFA / water
[0096] Mobile phase B: 0.1% TFA / acetonitrile
[0097] Gradient Program:
[0098] Time (minutes) Solvent B[%] 0.0 5 30.0 60 33.0 60 33.1 5 40.0 5
[0099] NMR analysis
[0100] NMR experiments were performed on a Bruker AVIII HD spectrometer equipped with a DCH cryogenic probe, operating at 500.12 MHz for protons and carbon. Experiments were performed in deuterated DMSO, and each sample was prepared to a concentration of approximately 10 mM. Further analysis was optionally performed in D2O and / or methanol-d4. Chemical shifts are expressed in parts per million (ppm, delta units). Coupling constants are expressed in Hz. The abbreviations for the multiplicities observed in the NMR spectra are as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad peak).
[0101] X-ray powder diffraction (XRPD)
[0102] XRPD analysis was performed on a PANalytical X'pert pro with a PIXcel detector (128 channels), scanning samples between 3-35° 2θ. The material was lightly ground to release any agglomerates and loaded onto a porous plate with a Mylar polymer film to support the sample. The porous plate was then placed in the diffractometer and the sample was analyzed using Cu Kα radiation ( α1:α2 ratio = 0.5) were analyzed in transmission mode (step size 0.0130° 2θ, step time 18.87 s) using a 40 kV / 40 mA generator setting. Data were visualized and images were generated using the Highscore Plus 4.7 desktop application (PANalytical, 2017).
[0103] Unless otherwise stated, solvents and reagents were purchased and used from commercial suppliers.
[0104] Example 1 : Synthesis and characterization of Form 1: Crystalline forms of the sesquisuccinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine
[0105] 514.6 mg of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine was weighed into a 20 mL scintillation vial. 10 mL of methyl ethyl ketone (99% pure) was added to the vial and the vial was stirred at 40°C using a temperature control block, a stirrer plate and a magnetic needle. No clear solution was observed, so 5 mL of MEK was further added to aid dissolution at 40°C. A clear solution was obtained; the clear solution at 40°C was fine filtered using a PTFE filter (0.45 micron) and a syringe. The filtered solution was added back to a clean 20 mL scintillation vial and reheated to 40°C. 142.5 mg of succinic acid (1 mol equivalent) was added to the vial. A clear solution was initially observed. After stirring at 40°C for 30 minutes, crystallization of the material was observed. The experiment was temperature cycled between 40°C and 5°C in 3 hour cycles for 20 hours. The slurry was filtered under vacuum using a grade 1 Whatman filter paper (pore size = 11 μm) at 5°C using a Buchner flask and funnel. The wet cake was washed with 2.5 mL of frozen (5°C) MEK and dried under reduced pressure at 40°C for 2 hours. The dried isolated solid was analyzed by XRPD and HPLC. The concentration of the filtered mother liquor was analyzed by HPLC.
[0106] The isolated yield was 78.5% and the HPLC yield based on the mother liquor concentration was 93.5% (see Table 1).
[0107] Table 1 : Preparation results of crystal form 1 succinate
[0108]
[0109] HPLC indicated 99.2% purity; rt = 10.65 min.
[0110] XRPD 2θ diffraction pattern shows that the material to be crystallized ( Figure 1 ), and when irradiated with a CuKα light source, it includes peaks at diffraction angles of 2θ = 3.8°±0.2° (100%), 10.3°±0.2° (11.3%), 12.4°±0.2° (6.8%), 16.2°±0.2° (23.5%), 17.9°±0.2° (11.9%), 19.8°±0.2° (10.2%), 20.4°±0.2° (13.0%), 23.8°±0.2° (23.3%) and 26.7°±0.2° (9.8%).
[0111] Another batch of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sesquisuccinate was prepared and further characterized by HPLC, XRPD and NMR.
[0112] HPLC showed a purity of 98.4%.
[0113] The XRPD 2θ diffraction pattern was identical to that of the previous batch.
[0114] DMSO-d6 1 H and quantitative 13 C NMR spectra are shown in Figure 5 and Figure 6 middle.
[0115] 1 H NMR spectrum (500.12 MHz-DMSO-d6): δ (ppm): 7.13 (2H dd J1=6 Hz, J2=3 Hz), 6.87 (2Hdd J1=6 Hz, J2=3 Hz), 6.71 (1H br s), 3.30 (2H t J=7 Hz), 2.42 (6H m, 2.33 4H dt J1=16 Hz, J2=7 Hz), 2.04 (4H d J=7 Hz), 1.74 (2H quintet J=7 Hz), 1.67 (2H septet J=7 Hz), 1.52 (2H quintet J=7 Hz), 0.85 (12H d J=7 Hz) ppm.
[0116] Quantification 13 C NMR spectrum (121.16 MHz-DMSO-d6): δ (ppm): 174.3, 156.0, 119.5, 111.9, 63.956.1, 55.6, 53.0 (d), 29.8, 26.8, 26.6, 24.2, 21.3. Quantitative 13 C NMR confirmed the stoichiometry and successful formation of the sesquisuccinate salt.
[0117] Biological Examples
[0118] The aim of the following study was to evaluate the neuroprotective effects of different concentrations of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) disulfate and N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) sesquisuccinate Form 1 on primary cultures of sensory neurons of dorsal root ganglia (DRG) that were damaged by a chemotherapeutic agent (cisplatin).
[0119] Primary culture of sensory neurons and Schwann cells
[0120] Primary sensory neurons (SN) and Schwann cells (SC) were cultured as previously described in Cancer Chem. Pharmacol. 2008 Nov; 62 (6): 995-1007. Briefly, female rats (Wistar rats; Janvier Labs France) at 15 days of gestation were sacrificed using deep anesthesia and cervical dislocation in a CO2 chamber. Then, the fetuses were collected and immediately placed in ice-cold L15 Leibovitz medium containing 2% penicillin (10,000 U / mL) and streptomycin (10 mg / mL) solution (PS) and 1% bovine serum albumin (BSA). The DRG of the spinal cord was treated with a trypsin-EDTA solution with a final concentration of 0.05% trypsin and 0.02% EDTA at 37°C for 20 minutes. Dissociation was terminated by adding Dulbecco's modified Eagle's medium (DMEM) containing 4.5g / L glucose, DNase I grade II (final concentration 0.5mg / mL) and 10% fetal calf serum (FCS). Cells were mechanically dissociated by the tip of a 10mL pipette. Then, the cells were centrifuged at 515x g for 10min at 4°C. DMEMF12 with 1% N2 supplement solution, 2mmol / L L-glutamine, 2% PS solution, NGF (5ng / mL) and NT3 (5ng / mL). Cells were seeded in a 96-well plate pre-coated with poly-L-lysine at a density of 15,000 / well and cultured in an air (95%)-CO2 (5%) incubator at 37°C.
[0121] Compound treatment
[0122] On day 14 of culture, primary SNs and SCs were exposed to the chemotherapeutic agent cisplatin (10 μg / mL, diluted in culture medium) for 24 hours in the presence of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) disulfate or N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) sesquisuccinate crystalline form. After 24 hours, the culture medium was removed (to wash away the cisplatin) and fresh culture medium containing sulfate or sesquisuccinate crystalline form 1 of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine was added for another 24 hours.
[0123] End point assessment
[0124] After 15 days of culture (24 hours after cisplatin injury), cell culture supernatants were collected and SNs were fixed with cold ethanol (95%) and acetic acid (5%) solutions at -20°C for 5 minutes. The cells were washed twice in PBS. The cell membranes were permeabilized and nonspecific sites were blocked with a PBS solution containing 0.1% saponin and 1% FCS for 15 minutes at room temperature. The cells were then incubated with a mouse monoclonal antibody anti-microtubule-associated protein 2 (MAP-2) at a dilution of 1 / 400 in PBS containing 1% fetal bovine serum and 0.1% saponin for 2 hours. The antibody specifically binds to MAP-2 present in the cell bodies and neurites of all SNs. The antibody was displayed with Alexa Fluor 488 goat anti-mouse IgG. The nuclei of neurons were labeled by fluorescent labeling (Hoechst solution).
[0125] For each condition, 30 pictures per well (representing 90% of the well area) were automatically taken at 20x magnification using ImageXpress (Molecular Devices). All images were taken under the same conditions (exposure time, gain, and laser intensity). The analysis of different endpoints was automated using Custom Module Editor (Molecular Devices).
[0126] The end point is:
[0127] -SN survival rate (number of MAP-2 positive SN)
[0128] - Total neurite network (MAP-2): total length of SN neurites (expressed in μm)
[0129] Statistical analysis
[0130] All values are expressed as mean + / - SEM. Statistical analysis was performed by one-way ANOVA followed by PLSDFisher test. Graphs and statistical analysis were performed under different conditions using Graphpad Prism software version 9.3.1, ####p<0.0001 compared to control (CTR); *p<0.05 for cisplatin (10 μg / mL); **p<0.01 and ***p<0.001 were considered significant.
[0131] result
[0132] 1-N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine)
[0133] Effect of disulfate
[0134] Sensory neuron survival: As expected, cisplatin intoxication significantly reduced SN survival compared with the control group (mean survival rate: 61%; Figure 7A). Several doses of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) disulfate (3 nM-100 nM) showed a positive and significant effect on survival compared to cisplatin conditions.
[0135] The maximum effect was obtained at a dose of 30 nM (mean survival rate: 80%).
[0136] SN neurite network integrity: Cisplatin significantly reduced the SN neurite network (~61%, Figure 7 B). Administration of different doses of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine) disulfate (3 nM-100 nM) was able to improve neurite networks after cisplatin injury, with the maximal effect at 30 nM (mean length: 83%).
[0137] 2-N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine)
[0138] Effect of Sesquisuccinate Form 1
[0139] Sensory neuron survival: As expected, cisplatin significantly reduced SN survival compared to the control group
[0140] Rate (average survival rate: 62%; Figure 8 A). Several doses of sesquisuccinate Form 1 (3 nM - 100 nM) showed a positive and significant effect on survival compared to cisplatin conditions. The maximum effect was obtained with a dose of 10 nM sesquisuccinate Form 1 (mean survival:
[0141] ~77%).
[0142] Neurite network integrity: Cisplatin strongly reduced the neurite network of SN (~63%, Figure 8 B).
[0143] All doses of 3 nM-100 nM sesquisuccinate Form 1 were able to protect neurite networks from cisplatin damage, with a maximal effect at 10 nM (average length: -80%).
Claims
1. Salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof for use in the treatment and / or prevention of sensory neuron diseases.
2. Salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof for use in delaying the onset of a sensory neuron disease in a patient.
3. The salt for use thereof according to claim 1 or 2, wherein the salt is selected from the group consisting of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sulfate and N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine succinate, and pharmaceutically acceptable solvates thereof.
4. The salt for use thereof according to claim 3, which has formula I wherein x is 0.5-4, and pharmaceutically acceptable solvates thereof.
5. The salt and pharmaceutically acceptable solvate thereof for use according to claim 4, characterized in that x is about 2.
6. The salt for use thereof according to claim 5, wherein the sulfate is N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulfate.
7. The salt for use thereof according to claim 3, which has the formula II wherein y is 1-4, and a pharmaceutically acceptable solvate.
8. The salt and pharmaceutically acceptable solvate thereof for use according to claim 7, characterized in that y is about 1.
5.
9. The salt for use thereof according to claim 8, wherein the succinate is N-(3-(4-(3-(Diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sesquisuccinate.
10. The salt for use thereof according to claim 8, wherein the succinate is N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine sesquisuccinate, a crystalline form of which has an X-ray powder diffraction (XRPD) pattern when irradiated with a CuKα light source, the pattern comprising peaks at diffraction angles at 2θ=3.8°±0.2°, 10.3°±0.2°, 12.4°±0.2°, 16.2°±0.2°, 17.9°±0.2°, 19.8°±0.2°, 20.4°±0.2°, 23.8°±0.2° and 26.7°±0.2°.
11. The salt for use thereof according to claim 1 or 2, wherein the sensory neuron disease is selected from the group consisting of neuropathy caused by Sjögren's syndrome, celiac disease neuropathy, toxic peripheral neuropathy and chemotherapy-induced neuropathy.
12. The salt for use thereof according to claim 11, wherein the sensory neuron disease is selected from the following: neuronopathy caused by Sjögren's syndrome, neuronopathy caused by celiac disease, toxic peripheral neuronopathy, chemotherapy-induced neuronopathy caused by platinum-based antitumor agents.
13. The salt for use thereof according to claim 12, wherein the sensory neuron disease is a chemotherapy-induced neuron disease caused by a platinum-based antitumor agent.
